WHO ICTRP trial
Assessing the potential of ivabradine and related drugs for the treatment of…
ISRCTN68734605 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN68734605 |
|---|---|
| Public title | Assessing the potential of ivabradine and related drugs for the treatment of nerve pain in patients |
| Scientific title | The role of HCN channel receptor in neuropathic pain: An open-label, single arm study of ivabradine in patients with peripheral neuropathic pain |
| Primary sponsor | Cambridge University Hospitals NHS Foundation Trust |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not Applicable |
| Countries | United Kingdom;England |
| Conditions | Specialty: Anaesthesia, perioperative medicine and pain management, Primary sub-specialty: Anaesthesia, Perioperative Medicine and Pain Management; UKCRC code/ Disease: Neurological/ Nerve, nerve root and plexus disorders Nervous System… |
| Interventions | All participants receive oral administration of Ivabradine. The dosage of ivabradine will range from 2.5 mg to 7.5 mg twice daily. The starting dose is 2.5mg twice daily for all participants, if tolerated, the dose will be increased every… |
| Registration date | Mar 14, 2017 |
| Target size | 50 |
| Secondary IDs | 32107 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: